Nanotechnology solutions for mucosal immunization

被引:151
作者
Chadwick, Sandra [1 ]
Kriegel, Christina [1 ]
Amiji, Mansoor [1 ]
机构
[1] Northeastern Univ, Dept Pharmaceut Sci, Sch Pharm, Boston, MA 02115 USA
关键词
Mucosal vaccination; Polymeric nanoparticles; Multiple emulsions; Immune-adjuvants; FOLLICLE-ASSOCIATED EPITHELIUM; TUBERCULOSIS DNA VACCINES; SYSTEMIC IMMUNE-RESPONSE; DRUG-DELIVERY; PROTECTIVE EFFICACY; M-CELLS; MULTIPLE EMULSIONS; ANTIBODY-RESPONSES; TARGETED DELIVERY; BLOCK-COPOLYMERS;
D O I
10.1016/j.addr.2009.11.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The current prevalence of infectious diseases in many developing regions of the world is a serious burden, impacting both the general health as well as economic growth of these communities. Additionally, treatment with conventional medication becomes increasingly challenging due to emergence of new and drug resistant strains jeopardizing the progress made in recent years towards control and elimination of certain types of infectious diseases. Thus, from a public health perspective, prevention such as through immunization by vaccination, which has proven to be most effective, might be the best alternative to prevent and combat infectious diseases in these regions. To achieve this, development of wide-scale immunization programs become necessary including vaccines that can easily and widely be distributed, stored and administered. Mucosal vaccines offer great potential since they can be administered via oral or intranasal delivery route which does not require trained personnel, avoids the use of needles and improves overall patient compliance and acceptance. However, it necessitates the implementation of specific immunization strategies to improve their efficacy. Application of nanotechnology to design and create particle mediated delivery systems that can efficiently encapsulate vaccine components for protection of the sensitive payload, target the mucosal immune system and incorporate mucosal adjuvants maximizing immune response is key strategy to improve the effectiveness of mucosal vaccines. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:394 / 407
页数:14
相关论文
共 140 条
[1]   TB vaccines: current status and future perspectives [J].
Aagaard, Claus ;
Dietrich, Jes ;
Doherty, Mark ;
Andersen, Peter .
IMMUNOLOGY AND CELL BIOLOGY, 2009, 87 (04) :279-286
[2]   The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization [J].
Akhiani, AA ;
Stensson, A ;
Schön, K ;
Lycke, N .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2006, 63 (02) :97-105
[3]   Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice [J].
Alignani, D ;
Maletto, B ;
Liscovsky, M ;
Rópolo, A ;
Morón, G ;
Pistoresi-Palencia, MC .
JOURNAL OF LEUKOCYTE BIOLOGY, 2005, 77 (06) :898-905
[4]   Squalene and squalane emulsions as adjuvants [J].
Allison, AC .
METHODS, 1999, 19 (01) :87-93
[5]   Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].
Amara, RR ;
Villinger, F ;
Altman, JD ;
Lydy, SL ;
O'Neil, SP ;
Staprans, SI ;
Montefiori, DC ;
Xu, Y ;
Herndon, JG ;
Wyatt, LS ;
Candido, MA ;
Kozyr, NL ;
Earl, PL ;
Smith, JM ;
Ma, HL ;
Grimm, BD ;
Hulsey, ML ;
Miller, J ;
McClure, HM ;
McNicholl, JM ;
Moss, B ;
Robinson, HL .
SCIENCE, 2001, 292 (5514) :69-74
[6]   Cholera toxin, E-coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches [J].
Anosova, N. G. ;
Chabot, S. ;
Shreedhar, V. ;
Borawski, J. A. ;
Dickinson, B. L. ;
Neutra, M. R. .
MUCOSAL IMMUNOLOGY, 2008, 1 (01) :59-67
[7]  
Azad N., 2006, AM J DRUG DELIV, V4, P79, DOI [DOI 10.2165/00137696-200604020-00003, 10.2165/00137696-200604020-00003]
[8]   Vaccine delivery: lipid-based delivery systems [J].
Baca-Estrada, ME ;
Foldvari, M ;
Babiuk, SL ;
Babiuk, LA .
JOURNAL OF BIOTECHNOLOGY, 2000, 83 (1-2) :91-104
[9]   Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens [J].
Bacon, A ;
Makin, J ;
Sizer, PJ ;
Jabbal-Gill, I ;
Hinchcliffe, M ;
Illum, L ;
Chatfield, S ;
Roberts, M .
INFECTION AND IMMUNITY, 2000, 68 (10) :5764-5770
[10]   Challenges in the development of an HIV-1 vaccine [J].
Barouch, Dan H. .
NATURE, 2008, 455 (7213) :613-619